Pharma & Bio
Business·Industry
K-Bio Secures Solid Funding… What Do They Have in Common?
Large-scale domestic capital is flowing into proven platform-based biotech companies, evolving into long-term growth funding for global new drug development.
Status of Large-Scale Investment Attrac…
Technology
LigaChem Biosciences’ ‘Hidden Cash Cow’ for the Second Half… Expectations for Revenue from Technology Transfer
LigaChem Biosciences(141080)is poised to benefit from two key drivers in the second half of the year: cash inflows and the release of key clinical data. This is because, amid growing expectations rega…
Technology
[Space Bio: Part 2] K-Bio Chases Big Pharma… Aims for Sovereignty in Space-Based New Drugs
The reasons why Korea’s pharmaceutical and biotech industries are turning their attention to space lie in cost and sovereignty. In a microgravity environment, the costs and time required for new drug …
Technology
Curiox Expands Business from 'Equipment' to 'Software'... Contract with Big Pharma Serves as a Signal
Curiox Biosystems Co., Ltd.(445680)(Curiox) is set to improve its earnings structure by expanding its software (SW) business. Having remained at around 5 billion won in revenue for several years since…
Business·Industry
'From HLB INC.’s Day of Reckoning to TG-C’s Revenge Match'… July’s Hot Topics in K-Bio [Monthly Spotlight]
The major events in the biotech industry in July can be summarized as the decision on whether to grant marketing approval for HLB INC.(028300) ’s new liver cancer drug, Riboceranib, and the release of…
Lifestyle
“12 Million Patients, Only One Treatment”… Mezion Pharma Co., Ltd. Sets Sights on Rare Kidney Disease as It Moves Directly to FDA Phase 2 Trials
“We’ve been preparing for the post-Fontan era.” Following its treatment for a rare heart disease— Mezzion Pharma Co., Ltd.(140410)—is now positioning autosomal dominant polycystic kidney disease (ADPK…
Technology
Yoo Sang-gu, CEO of Glaseum: “We Expect Synergy with DaewonPharmaceutical’s Quadruple-Action Agent… We’re Focusing on Fat Loss”
The global obesity treatment market is evolving beyond glucagon-like peptide-1 (GLP-1)-based therapies toward triple- and quadruple-action drugs. Among domestic pharmaceutical companies, DaewonPharmac…
Technology
Nam Byung-ho, CEO of Herings: "Software Agreement with the Luxembourg Government... Expects Sales in Europe"
"Herrings has been selected as a partner for Luxembourg’s national disease management project. This achievement is believed to have been made possible thanks to the strong recommendation by Dr. Liners…
Technology
Will HASS Corp. Break Its Three-Year Sales Stagnation?… Challenging Zirconia’s Dominance with New Products
HASS Corp.(450330), which has seen stagnant sales for the past three years, is aiming to reshape the zirconia-based dental restoration materials market with a new lithium disilicate product that can b…
Lifestyle
EyeGene,Inc Begins Preparations to Export Recombinant Botox... Expectations for a Rebirth as a Profitable Company
EyeGene,Inc(185490)is set to reinvent itself as a company generating its own revenue, led by its next-generation botulinum toxin product based on recombinant DNA technology. The company plans to break…